Colicchia, A. and Fabian, D. and Grabenhofer, L. and Grössmann-Waniek, N. and Malíková, E. and Rothschedl, E. and Sehic, O. and Wild, C. and Wolf, S. and Zechmeister-Koss, I. (2025): Fidanacogene elaparvovec (BEQVEZ®) for the treatment of moderately severe to severe haemophilia B. Decision Support Document for the Austrian Appraisal Board 002.

Erdos, J. and Sehic, O. and Wild, C. (2021): ≥ 12 Month Follow-Up of Patients with Spinal Muscular Atrophy (SMA) treated with Spinraza®, Zolgensma® or Combination Therapies. AIHTA Policy Brief 001/ 1. Update.

Falkner, E. and Wild, C. (2008): Clinical application of Tissue Engineering: An overview of International and Austrian Areas of Research with a critical analysis of selected applications . LBI-HTA Projektbericht 013.

Geiger-Gritsch, S. (2020): CAR-T Cell Therapies, ATMP and Gene Therapies in Development, Horizon Scanning: CAR-T Cell Therapy. AIHTA Policy Brief 006a.

Geiger-Gritsch, S. and Absenger, G. and Endel, F. and Flicker, M. and Hermann, A. and Kocher, F. and Olschewski, H. and Pall, G. and Wurm, M. and Zechmeister, M. (2021): Health Services Research in Oncology: Patients with Non-Small Cell Lung Cancer Treated with Anti-PD-1/PD-L1 Therapy in Real-World Practice. A Pilot Project in Cooperation with Tirol Kliniken GmbH & KAGes. HTA-Projektbericht 126.

Giess, D. and Erdos, J. and Wild, C. (2023): SMA-Therapies: Mid- to longer-term follow-up of spinal muscular atrophy (SMA) patients treated for ≥24 months with nusinersen or onasemnogene abeparvovec as monotherapies or in combination, and patients treated for ≥12 months with risdiplam as monotherapy or in combination. AIHTA Policy Brief 001/ 2. Update.

Glanz, K.A. (2021): Nivolumab in malignant melanoma: contrasting the evidence from pivotal trials with Real World Evidence (RWE). HTA-Projektbericht 140.

Jeindl, R. and Mayer-Ferbas, J. (2024): CAR-based immunotherapy with a focus on CAR-NK cells. Rapid Review Nr.: 013.

Panhuber, A. and Titieni-Schuhmann, A. and Goetz, G. and Wild, C. (2022): CAR-T cell therapy: Contrasting the evidence from pivotal trials with the real world evidence (RWE). HTA-Projektbericht 146.

Radlberger, P. (2007): [Genotyping for Cytochrome P450 Polymorphisms]. HTA-Newsletter 53: p. 3.

Sehic, O. and Wild, C. (2022): ATMPs and Gene Therapies in Development. Horizon Scanning – Update 2022. AIHTA Policy Brief 006b/ 1. Update.

Wild, C. and Wohlhöfner, K. and Sehic, O. and Grössmann, N. (2020): CAR-T Cell Therapies, ATMP and Gene Therapies in Development, Horizon Scanning: ATMPs and Gene Therapies. AIHTA Policy Brief 006b.

Wild, C. (2005): [Genotyping for cytochrome P450 polymorphisms]. HTA-Newsletter 33: pp. 2-3.

Wild, C. (2002): [Pharmacogenetics]. HTA-Newsletter 13: p. 4.

Wild, C. and Grössmann, N. (2019): FoundationOne®CDx: genetic profiling of solid tumours. Rapid Assessment 014.